Diabetes

Learn the fascinating details of the discovery of incretin-active agents, including DPP4 inhibitors, GLP-1 agonists, and GLP-2 agonists.

New blood glucose monitoring system transfers data to iOS devices using the headphone jack, rather than an adaptor or other technology.

The NephroCheck test detects levels of 2 AKI markers, which can determine whether the condition will progress to moderate or severe injury.

A model used in 3 studies was found to accurately predict serious complications in patients with type 1 diabetes.

Children and adolescents who received antipsychotic medications had an increased absolute risk of developing type 2 diabetes.

Adolescents exposed to gestational diabetes in utero have a higher risk of developing impaired glucose tolerance.

The FDA has approved the first zinc transporter 8 autoantibody test that may help patients with type 1 diabetes mellitus receive more timely diagnosis and treatment for the disease.

A new drug was recently given tentative approval by the FDA to help patients with both type 1 and type 2 diabetes.

A patient's lifetime risk of developing type 2 diabetes currently stands at 40%, with an even higher risk for some ethnic groups.

Jesse McCullough, PharmD, director of field clinical services for Rite Aid, discusses the implications of a pharmacist-led intervention to boost medication adherence.

Community pharmacists dramatically boost medication adherence among patients with chronic conditions.

In a recent study, patients with diabetes who were referred to a pharmacist-led clinic by their primary care providers saw their mean HbA1C levels fall by 2.4%.

American adults are eating too little fish to meet current recommendations for fish-derived omega-3 fatty acids.

Moderate intake of long chain omega-3 polyunsaturated fatty acids as a lipid-lowering strategy appears to have no effects on glucose regulation or insulin resistance.

Researchers in Taiwan have found an increased risk for head and neck cancers among patients with diabetes mellitus.

Researchers in Taiwan have found an increase in the risk for head and neck cancers among patients with diabetes mellitus (DM) equivalent to approximately 2.6 additional cases per 10,000 person-years in patients with DM versus patients without DM.

Diabetes control worsened for patients with diabetes who received or were receiving androgen deprivation therapy for prostate cancer.